Articles tagged "Hepatocellular carcinoma"

2022 American Transplant Congress
Locoregional Therapy and Long-Term Post-Transplant Outcomes for HCC Liver Transplant Recipients
T. Ishaque, S. R. Weeks, A. Kolarich, J. Ruck, J. Garonzik-Wang, D. Segev, A. Massie, B. King
Johns Hopkins Medical Institutions, Baltimore, MD
*Purpose: In last decade, locoregional therapy (LRT) have been widely used to downstage HCC patients in order to qualify for liver transplantation. Large-scale direct comparisons…
2022 American Transplant Congress
Degree of Pre-Liver Transplant Immune Dysfunction Correlates with Post-Transplant Cancer Recurrence
G. S. Prakash¹, G. G. Panayotova¹, S. Simonishvili¹, Y. Qin¹, L. Jin¹, T. Ayorinde¹, L. J. Minze², F. Paterno¹, L. Brown¹, A. Amin¹, D. Liu¹, R. Ghobrial², J. V. Guarrera¹, K. E. Lunsford¹
¹Rutgers New Jersey Medical School, Newark, NJ, ²Houston Methodist Hospital, Houston, TX
*Purpose: Despite stringent selection criteria for liver transplant (LT) in patients with liver-limited malignancy, post-transplant cancer recurrence remains problematic. We have previously identified a pre-LT…
2022 American Transplant Congress
The Impact of Yttium-90 Radioembolization on T Cell Phenotypes in Bridged to Transplant Hepatocellular Carcinoma Patients
K. Nunez, T. Sandow, P. Thevenot, A. Cohen
Ochsner Health System, New Orleans, LA
*Purpose: Response to locoregional therapy (LRT) in hepatocellular carcinoma (HCC) impacts both progression-free survival (PFS) and bridge to transplant success. Yttrium-90 (Y90) is an effective…
2022 American Transplant Congress
Clinical Efficacy of Adjuvant Immunotherapy for Liver Transplant Recipients with Exceeding Japan Criteria of Hepatocellular Carcinoma Using Donor Liver Derived Natural Killer Cells
M. Ohira¹, Y. Imaoka², K. Sato³, K. Imaoka¹, N. Tanimine¹, H. Tahara¹, K. Ide¹, T. Kobayashi¹, Y. Tanaka¹, A. G. Tzakis⁴, S. Nishida⁵, H. Ohdan¹
¹Hiroshima University, Hiroshima, Japan, ²Hiroshima Uni., Hiroshima, Japan, ³Department of Gastroenterological and Transplant Surgery, Hiroshima University, Hiroshima, Japan, ⁴Digestive Diseases and Surgery Institute, Cleveland Clinic, Cleveland, OH, ⁵Univ of Miami School of Medicine, Valhalla, NY
*Purpose: Hepatocellular carcinoma (HCC) is one of the most common cancers worldwide and is an indication for liver transplantation (LT). Immunosuppressive regimens currently used after…
2022 American Transplant Congress
Impact of MMaT Policy on Transplant for Hepatocellular Carcinoma at a Single Center
S. Kodali¹, D. W. Victor², J. Corkrean², A. Shetty², C. Mobley², M. Hobeika², R. McMillan², E. A. Graviss³, D. T. Nguyen³, R. McFadden⁴, V. Ankoma-Sey², C. Egwim⁵, J. Galati², A. Saharia², R. M. Ghobrial²
¹Sherrie and Alan Conover Center for Liver Disease and Transplantation, Houston Methodist Hospital, Sugarland, TX, ²Sherrie and Alan Conover Center for Liver Disease and Transplantation, Houston Methodist Hospital, Houston, TX, ³Department of Pathology and Genomic Medicine, Houston Methodist Hospital, Houston, TX, ⁴Department of Medicine, Hepatology, Houston Methodist Hospital, Houston, TX, ⁵Houston Methodist Hospital, Houston, TX
*Purpose: Hepatocellular carcinoma (HCC) is the most common primary malignant hepatic tumor. Currently, liver transplantation may be the optimal treatment for HCC. Patient selection criteria…
2022 American Transplant Congress
Induction Immunosuppression Does Not Worsen Tumor Recurrence After Liver Transplantation for T2 Hepatocellular Carcinoma and May Allow for Decreased Mortality
C. Durkin¹, T. Bittermann¹, D. E. Schaubel²
¹Gastroenterology, University of Pennsylvania, Philadelphia, PA, ²Biostatistics, University of Pennsylvania, Philadelphia, PA
*Purpose: Prior studies have suggested that induction therapy leads to worse outcomes after liver transplantation (LT) for hepatocellular carcinoma (HCC). This study evaluated the impact…
2022 American Transplant Congress
A Intention-to-Treat Analysis of 881 Consecutively Waitlisted Patients to Develop a Survival Benefit Model for Hepatocellular Carcinoma Liver Transplant Candidates
B. V. Tran¹, W. Lapisatepun¹, W. Dumronggittigule¹, D. Markovic², Y. Lee¹, F. Kaldas¹, D. Farmer¹, R. Busuttil¹, V. Agopian¹
¹Department of Surgery, University of California Los Angeles, Los Angeles, CA, ²Department of Medicine, Statistics Core, University of California Los Angeles, Los Angeles, CA
*Purpose: The current liver transplantation (LT) selection paradigm for hepatocellular carcinoma (HCC) patients ignores the variable risks of waitlist dropout and post-LT recurrence/death, with the…
2022 American Transplant Congress
Increased Regulatory T-cells in Tumor Microenvironment is Associated with Hepatocellular Carcinoma Differentiation in Patients Undergoing Liver Transplantation
G. Orozco¹, R. Gedaly², L. Turcios², F. Marti²
¹Surgery, University of Kentucky, Lexington, KY, ²UKHC, Lexington, KY
*Purpose: Tumor-infiltrating lymphocytes are an essential component of the tumor microenvironment. The balance between cytotoxic effector T cells and immunosuppressive regulatory T cells is critical…
2022 American Transplant Congress
Immune Checkpoints, Immune Cells, and MHC Expression in the Tumor Microenvironment of Resected Hepatocellular Carcinomas
A. Baquerizo¹, V. Vavinskaya², S. Bagsic¹, A. Rojas³, A. Mhoyan⁴, C. Frenette¹, L. Sher⁵, M. Romero³, J. Fisher¹, C. Marsch¹, R. Schaffer¹
¹Scripps, La Jolla, CA, ²UCSD, San Diego, CA, ³University, Seville, Spain, ⁴Kaiser, San Diego, CA, ⁵USC, Los Angeles, CA
*Purpose: Advances in tumor biology has shown the important role of the tumor microenvironment (TME) in tumor growth and metastasis. A better understanding of the…
2022 American Transplant Congress
Disparities in Liver Transplantation in Patients with HCC Diagnosis
C. Warren¹, A. Zarrinpar²
¹Surgery, University of Florida Shands Health, Gainesville, FL, ²Surgery, University of Florida Health Shands, Gainesville, FL
*Purpose: Disparities in outcomes of hepatocellular carcinoma (HCC) have not been adequately studied, especially in the context of liver transplantation (LT). We sought to identify…